Clinical Trial Update: Double-Blind, Dose-Escalation Study of IDX184 in Chronic Hepatitis C Treatment-Naïve Subjects [Phase 1, Phase 2]

View source ↗

Summary

ClinicalTrials.gov entry reports the results of a double-blind, dose-escalation study of IDX184 in treatment-naïve chronic hepatitis C patients, spanning Phase …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• IDX184 (IDX184)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Chronic Hepatitis C (HCV) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2010-11-04